| Title |
Levofloxacin in the treatment of complicated urinary tract infections and acute pyelonephritis
|
|---|---|
| Published in |
Therapeutics and Clinical Risk Management, October 2008
|
| DOI | 10.2147/tcrm.s3426 |
| Pubmed ID | |
| Authors |
Jessina C McGregor, George P Allen, David T Bearden |
| Abstract |
Levofloxacin is a widely used fluoroquinolone approved for the treatment of complicated urinary tract infections and acute pyelonephritis. A comprehensive review of the medical literature identified five publications evaluating levofloxacin for the treatment of either complicated urinary tract infections or acute pyelonephritis. All trials, although variable in their inclusion criteria and levofloxacin dosing strategies, reported microbiologic, clinical, and safety-related outcomes. High microbiologic eradication rates, ranging from 79.8% to 95.3%, were observed in all studies. Escherichia coli was the most commonly isolated uropathogen. Data on levofloxacin resistance, both at baseline and after therapy, were limited. Clinical success was observed to range from 82.6% to 93% when measured after the completion of therapy. These clinical and microbiologic results were comparable to the fluoroquinolone comparators in all trials. Insufficient data are available to evaluate the outcomes in any meaningful patient subgroups, including catheterized patients, and those with other specific complicating factors. Levofloxacin was well tolerated in these studies, with headache, gastrointenstinal effects, and dizziness being the most commonly reported adverse events. The published data support the use of levofloxacin in complicated urinary tract infections and acute pyelonephritis. Further trials are necessary to evaluate levofloxacin within specific patient sub-populations. |
Mendeley readers
The data shown below were compiled from readership statistics for 83 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Arab Emirates | 1 | 1% |
| Unknown | 82 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 10 | 12% |
| Student > Master | 10 | 12% |
| Student > Bachelor | 10 | 12% |
| Student > Ph. D. Student | 7 | 8% |
| Researcher | 6 | 7% |
| Other | 18 | 22% |
| Unknown | 22 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 29% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 10% |
| Chemistry | 7 | 8% |
| Nursing and Health Professions | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Other | 12 | 14% |
| Unknown | 26 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 June 2022.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from Therapeutics and Clinical Risk Management
#461
of 1,323 outputs
Outputs of similar age
#36,704
of 101,353 outputs
Outputs of similar age from Therapeutics and Clinical Risk Management
#6
of 13 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,323 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.6. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 101,353 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.